Literature DB >> 22859922

Assessment of synovitis to predict bone erosions in rheumatoid arthritis.

Serena Bugatti1, Antonio Manzo, Roberto Caporali, Carlomaurizio Montecucco.   

Abstract

Although rheumatoid arthritis (RA) is traditionally considered as the prototype of destructive arthritis, the course of the disease varies considerably, with some patients experiencing more rapid progression of joint damage and disability than others. Given the increasing availability of treatment targets and options, timely recognition of individual's outcomes could allow therapeutic allocation according to personalized benefit-risk profiles. Research efforts are thus increasingly focused at discovering predictive markers that could identify patients with aggressive, rapidly progressive disease and poor prognosis. As joint destruction in RA is the result of the cumulative burden of inflammation, variables reflecting the severity of synovitis and its persistence over time might refine our ability to build early prognostic algorithms. The goal of this article is to review the clinical implications of the assessment of synovitis in relation to radiographic outcomes. Traditional and novel assessment tools will be discussed, including clinical measures, imaging techniques and tissue biomarkers. Achievements in the field of synovial tissue analysis and peripheral blood biomarkers of synovitis represent only the first steps of ongoing progress, which still need to be integrated into the phenotypic heterogeneity of RA.

Entities:  

Keywords:  biomarker; bone erosion; rheumatoid arthritis; synovitis

Year:  2012        PMID: 22859922      PMCID: PMC3403256          DOI: 10.1177/1759720X12453092

Source DB:  PubMed          Journal:  Ther Adv Musculoskelet Dis        ISSN: 1759-720X            Impact factor:   5.346


  85 in total

1.  Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.

Authors:  J J Haringman; D M Gerlag; A H Zwinderman; T J M Smeets; M C Kraan; D Baeten; I B McInnes; B Bresnihan; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

2.  T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis.

Authors:  M C Kraan; J J Haringman; H Weedon; E C Barg; M D Smith; M J Ahern; T J M Smeets; F C Breedveld; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis.

Authors:  P C Taylor; A Steuer; J Gruber; D O Cosgrove; M J K Blomley; P A Marsters; C L Wagner; C McClinton; R N Maini
Journal:  Arthritis Rheum       Date:  2004-04

4.  Prognostic laboratory markers of joint damage in rheumatoid arthritis.

Authors:  E Lindqvist; K Eberhardt; K Bendtzen; D Heinegård; T Saxne
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

Review 5.  OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system.

Authors:  Mikkel Østergaard; Charles Peterfy; Philip Conaghan; Fiona McQueen; Paul Bird; Bo Ejbjerg; Ron Shnier; Philip O'Connor; Mette Klarlund; Paul Emery; Harry Genant; Marissa Lassere; John Edmonds
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

6.  Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis.

Authors:  P A Klimiuk; S Sierakowski; R Latosiewicz; J P Cylwik; B Cylwik; J Skowronski; J Chwiecko
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

7.  Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis.

Authors:  E Lindqvist; K Jonsson; T Saxne; K Eberhardt
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

8.  Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).

Authors:  K Forslind; M Ahlmén; K Eberhardt; I Hafström; B Svensson
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

9.  Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.

Authors:  O Meyer; C Labarre; M Dougados; Ph Goupille; A Cantagrel; A Dubois; P Nicaise-Roland; J Sibilia; B Combe
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

Review 10.  Homing chemokines in rheumatoid arthritis.

Authors:  Pius Loetscher; Bernhard Moser
Journal:  Arthritis Res       Date:  2002-01-31
View more
  12 in total

1.  Joint blood flow is more sensitive to inflammatory arthritis than oxyhemoglobin, deoxyhemoglobin, and oxygen saturation.

Authors:  Ajay Rajaram; Seva Ioussoufovitch; Laura B Morrison; Keith St Lawrence; Ting-Yim Lee; Yves Bureau; Mamadou Diop
Journal:  Biomed Opt Express       Date:  2016-09-01       Impact factor: 3.732

Review 2.  The draining lymph node in rheumatoid arthritis: current concepts and research perspectives.

Authors:  Francesca Benaglio; Barbara Vitolo; Martina Scarabelli; Elisa Binda; Serena Bugatti; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

3.  Synovial fluid proteome in rheumatoid arthritis.

Authors:  Mitali Bhattacharjee; Lavanya Balakrishnan; Santosh Renuse; Jayshree Advani; Renu Goel; Gajanan Sathe; T S Keshava Prasad; Bipin Nair; Ramesh Jois; Subramanian Shankar; Akhilesh Pandey
Journal:  Clin Proteomics       Date:  2016-06-05       Impact factor: 3.988

4.  Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort.

Authors:  Harris A Ahmad; Evo Alemao; Zhenchao Guo; Christine K Iannaccone; Michelle L Frits; Michael Weinblatt; Nancy A Shadick
Journal:  Adv Ther       Date:  2018-01-25       Impact factor: 3.845

5.  Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis.

Authors:  Serena Bugatti; Ludovico De Stefano; Antonio Manzo; Garifallia Sakellariou; Blerina Xoxi; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-22       Impact factor: 5.346

6.  Is painless synovitis different from painful synovitis? A controlled, ultrasound, radiographic, clinical trial.

Authors:  Daniele Freitas Pereira; Jamil Natour; Ana Leticia Pirozzi de Buosi; Fernando Bernardes Maia Diniz Ferreira; Artur da Rocha Corrêa Fernandes; Rita Nely Vilar Furtado
Journal:  Clinics (Sao Paulo)       Date:  2014-02       Impact factor: 2.365

Review 7.  B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.

Authors:  Serena Bugatti; Barbara Vitolo; Roberto Caporali; Carlomaurizio Montecucco; Antonio Manzo
Journal:  Biomed Res Int       Date:  2014-04-29       Impact factor: 3.411

Review 8.  Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Authors:  Ennio Giulio Favalli; Serena Bugatti; Martina Biggioggero; Roberto Caporali
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

9.  Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register.

Authors:  Daniel F McWilliams; David A Walsh
Journal:  BMC Musculoskelet Disord       Date:  2016-08-12       Impact factor: 2.362

10.  Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.

Authors:  Serena Bugatti; Laura Bogliolo; Barbara Vitolo; Antonio Manzo; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.